🔬 The Coolest Diffusion Research Isn't in LLMs — Evan Feinberg & Sergey Edunov, Genesis Molecular AI
Quick Answer
Evan Feinberg's departure from Meta to Genesis Molecular AI highlights a shift towards drug discovery, emphasizing PEARL's zero-shot OpenBind success.
Quick Take
Evan Feinberg's departure from Meta to Genesis Molecular AI highlights a shift towards drug discovery, emphasizing PEARL's zero-shot OpenBind success. The advancement in co-folding techniques is set to enhance accuracy, potentially revolutionizing molecular interactions and drug design.
Key Points
- Evan Feinberg left Meta to focus on drug discovery at Genesis Molecular AI.
- PEARL achieved a zero-shot win with its OpenBind model, showcasing significant capabilities.
- Advancements in co-folding are expected to surpass current accuracy thresholds.
- Improved molecular interaction modeling could accelerate drug design processes.
- The research indicates a growing intersection between AI and pharmaceutical development.
Article Excerpt
From source RSS / original summaryWhy the Llama lead left Meta for drug discovery, PEARL's zero-shot OpenBind win, and what becomes possible when co-folding finally crosses the accuracy threshold.
Want this in your inbox every morning?
Daily brief at your local 8am — bilingual EN/中文, free.
More from Latent Space
See more →
AIEWF Daily Dispatch: Loops, Software Factories & Forward Deployed Engineers
At the AI Engineer World's Fair, discussions centered on the rise of software factories and agent engineering, highlighting the importance of open models in enhancing development efficiency. The event showcased innovative approaches to loops in AI, emphasizing their role in optimizing software production and deployment.
![[AINews] Founders and Forward Deployed Engineers](https://substackcdn.com/image/fetch/$s_!SpLP!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fb92541e3-151a-4f10-8226-b86cb12eaca0_2332x1344.png)